Mitesh Parekh, MD
Urogynecology and Reconstructive Pelvic Surgery · Zanesville, OHNPI 1053376764
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (39.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 44 manufacturers reported payments, led by AbbVie at 29.4% of the total. 2025 is the largest year on record at $8,904, 4.9 times the $1,832 reported in 2019. Among urogynecology and reconstructive pelvic surgery clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 791 payments — averaging $41.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$10K
- Medtronic$9K
- Sumitomo Pharma America, Inc.$2K
- Boston Scientific$2K
- Kowa Pharmaceuticals America, Inc.$2K
- Axonics, Inc.$2K
- plus $7K from 38 others
Across 23 payments — averaging $5181.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Coloplast$101K
- Ironwood Pharmaceuticals, Inc$18K
- Medtronic$337
What the payments were for
- Consulting fees$2,1857%
- Speaking & faculty fees$13,25640%
- Travel & lodging$4,58114%
- Food & beverage$12,62038%
- Education$5482%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LINZESS$8,400
- INTERSTIM$7,118
- Seglentis$1,635
- GENERAL - THERAPIES$1,205
- Axonics$1,014
- NURO$550
- GEMTESA$363
- ALTIS$169
- Solyx SIS System$160
- Urgent PC Neuromodulation System$133
How this compares
$33,189 in reported general payments places this provider in the 90th percentile of 60 urogynecology and reconstructive pelvic surgery providers in Ohio.
See all urogynecology and reconstructive pelvic surgery providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SucraidSacrosidase | 35 | $533,759 |
| MyrbetriqMirabegron | 456 | $310,689 |
| GemtesaVibegron | 381 | $242,964 |
| LinzessLinaclotide | 105 | $101,960 |
| CreonLipase/Protease/Amylase | 13 | $45,450 |
| PremarinEstrogens, Conjugated | 103 | $44,881 |
| Estradiol | 461 | $31,720 |
| EstringEstradiol | 50 | $26,592 |
| Solifenacin Succinate | 702 | $22,281 |
| MotegrityPrucalopride Succinate | 20 | $16,383 |
| Methenamine Hippurate | 211 | $15,535 |
| Mirabegron ErMirabegron | 26 | $14,061 |
| Colestipol Hcl | 157 | $11,568 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 86 | $8,964 |
| MovantikNaloxegol Oxalate | 14 | $6,460 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| QOL Medical, LLCSucraid | $763 | $533,75935 claims |
| Astellas Pharma US IncMyrbetriq | $1,425 | $310,689456 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $2,055 | $242,964381 claims |
| AbbVieLinzess, Creon | $9,755 | $147,409118 claims |
| PfizerPremarin, Estring | $874 | $71,473153 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $390 | $16,38320 claims |
| Duchesnay USA IncorporatedOsphena | $11 | $3,36814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 60 urogynecology and reconstructive pelvic surgery providers in Ohio.
Other urogynecology and reconstructive pelvic surgery in Zanesville
- Costas ApostolisStrongsville$982K
- Mickey KarramWest Chester$127K
- Sangeeta MahajanMayfield Hts$48K
- Emily SlopnickCleveland$37K
- Andrew CroakMaumee$26K
- Ly Hoang RobertsCleveland$23K
- Marie ParaisoCleveland$20K
- Omer AnisCleveland$17K
- Nadine KassisToledo$15K
- Chen ShenharCleveland$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.